Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, unmarried females age 16 to 23 years with intact uteri~* Not pregnant at enrollment~* Agreed to use effective contraception through Month 7 of the study~* A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse~Exclusion Criteria:~* No prior history of Human Papillomavirus (HPV) vaccination~* No receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine~* No prior history of an abnormal Papanicolaou (Pap) test showing Squamous intraepithelial lesion (SIL) or biopsy showing Cervical intraepithelial neoplasia (CIN)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): HPV 16 L1 VLP vaccine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).